What are the indications for ceftriaxone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ceftriaxone Indications

Ceftriaxone is indicated for a broad range of bacterial infections including lower respiratory tract infections, acute bacterial otitis media, skin and soft tissue infections, urinary tract infections, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, and surgical prophylaxis 1.

FDA-Approved Indications

The FDA label provides comprehensive guidance on ceftriaxone's approved uses 1:

Respiratory Infections

  • Lower respiratory tract infections caused by S. pneumoniae, S. aureus, H. influenzae, H. parainfluenzae, K. pneumoniae, E. coli, E. aerogenes, P. mirabilis, or S. marcescens

Ear Infections

  • Acute bacterial otitis media caused by S. pneumoniae, H. influenzae (including beta-lactamase producing strains), or M. catarrhalis (including beta-lactamase producing strains)
    • Note: Single-dose ceftriaxone may have lower clinical cure rates compared to 10 days of oral therapy in some studies, though comparable rates were observed in others 1

Skin and Soft Tissue

  • Skin and skin structure infections caused by S. aureus, S. epidermidis, S. pyogenes, Viridans group streptococci, E. coli, E. cloacae, K. oxytoca, K. pneumoniae, P. mirabilis, M. morganii, P. aeruginosa, S. marcescens, A. calcoaceticus, B. fragilis, or Peptostreptococcus species

Urinary Tract

  • Complicated and uncomplicated urinary tract infections caused by E. coli, P. mirabilis, P. vulgaris, M. morganii, or K. pneumoniae

Sexually Transmitted Infections

  • Uncomplicated gonorrhea (cervical/urethral and rectal) caused by N. gonorrhoeae, including both penicillinase- and non-penicillinase-producing strains
  • Pharyngeal gonorrhea caused by non-penicillinase-producing strains of N. gonorrhoeae
  • Pelvic inflammatory disease caused by N. gonorrhoeae
    • Critical caveat: Ceftriaxone has no activity against C. trachomatis, so appropriate antichlamydial coverage must be added when treating PID 1

Systemic Infections

  • Bacterial septicemia caused by S. aureus, S. pneumoniae, E. coli, H. influenzae, or K. pneumoniae

Bone and Joint

  • Bone and joint infections caused by S. aureus, S. pneumoniae, E. coli, P. mirabilis, K. pneumoniae, or Enterobacter species

Intra-abdominal

  • Intra-abdominal infections caused by E. coli, K. pneumoniae, B. fragilis, Clostridium species (most strains of C. difficile are resistant), or Peptostreptococcus species

Central Nervous System

  • Meningitis caused by H. influenzae, N. meningitidis, or S. pneumoniae
    • Also successfully used in limited cases of meningitis and shunt infection caused by S. epidermidis and E. coli 1

Surgical Prophylaxis

  • Preoperative prophylaxis: A single 1 gram dose may reduce postoperative infections in contaminated or potentially contaminated surgical procedures 1

Pediatric-Specific Indications

The 2021 AAP guidelines provide detailed age-stratified recommendations for febrile infants 2:

Febrile Infants (22-60 days old)

  • UTI: Ceftriaxone 50 mg/kg/dose IV or IM every 24 hours
  • No focus identified (possible bacteremia): Ceftriaxone 50 mg/kg/dose IV or IM every 24 hours
  • Bacterial meningitis (29-60 days): Ceftriaxone 100 mg/kg/day IV once daily or divided every 12 hours

Neonatal Gonococcal Infections

CDC guidelines detail specific neonatal uses 3, 4, 5:

  • Gonococcal ophthalmia neonatorum: Ceftriaxone 25-50 mg/kg IV or IM (not to exceed 125 mg) in a single dose
  • Disseminated gonococcal infection (sepsis, arthritis, meningitis): Ceftriaxone 25-50 mg/kg/day IV or IM for 7 days (10-14 days if meningitis documented)
  • Prophylaxis for infants of mothers with untreated gonorrhea: Ceftriaxone 25-50 mg/kg IV or IM (not to exceed 125 mg) in a single dose

Pediatric Gonococcal Infections

For children weighing <45 kg 5:

  • Uncomplicated vulvovaginitis, cervicitis, urethritis, pharyngitis, or proctitis: Ceftriaxone 125 mg IM in a single dose
  • Bacteremia or arthritis: Ceftriaxone 50 mg/kg (maximum 1 g) IM or IV daily for 7 days

Adult Gonococcal Infections

Historical CDC guidelines established ceftriaxone as first-line therapy 3, 6:

  • Uncomplicated gonorrhea: Ceftriaxone 125 mg IM in a single dose (now 500 mg per current guidelines not in evidence)
  • Gonococcal conjunctivitis: Ceftriaxone 1 g IM in a single dose with saline lavage 6
  • Disseminated gonococcal infection: Ceftriaxone 1 g IM or IV every 24 hours initially, then switch to oral therapy after 24-48 hours of improvement 6

Meningitis in Adults

The 2016 UK guidelines support ceftriaxone for bacterial meningitis 7:

  • Suspected meningitis: Ceftriaxone 2 g IV twice daily
  • Outpatient therapy (after 5 days inpatient): Ceftriaxone 2 g IV twice daily, or 4 g once daily after the first 24 hours
  • Penicillin-resistant pneumococci: Ceftriaxone 2 g IV twice daily plus rifampicin 600 mg twice daily orally

WHO Essential Medicines Recommendations

The 2024 WHO guidelines classify ceftriaxone as an "Access" antibiotic for bacterial meningitis 8:

  • Recommended for patients aged 3 months and older
  • For patients <3 months: Use cefotaxime and amoxicillin/ampicillin instead
  • Add vancomycin for patients with prolonged antibiotic exposure or travel outside endemic areas

Important Prescribing Considerations

Antimicrobial Stewardship

  • Prescribe only for proven or strongly suspected bacterial infections to reduce development of drug-resistant bacteria 1
  • Obtain appropriate specimens for culture before initiating therapy, though treatment may begin before results are available 1

Special Populations

  • Renal impairment: No dosage adjustment needed for usual doses 1
  • Hepatic dysfunction alone: No adjustment needed 1
  • Combined hepatic and renal dysfunction: Do not exceed 2 grams daily and monitor closely 1
  • Hyperbilirubinemic infants: Use cautiously, especially in premature infants 5

Critical Safety Warnings

  • Monitor prothrombin time in patients with impaired vitamin K synthesis or low stores 1
  • Gallbladder pseudolithiasis: Reversible upon discontinuation; more common in pediatric patients 1
  • Urolithiasis: Can cause urinary tract precipitates; ensure adequate hydration 1
  • No activity against C. trachomatis: Always add appropriate coverage when treating PID or suspected coinfection 1

References

5
Guideline

sexually transmitted diseases treatment guidelines, 2006.

MMWR Recommendations and Reports, 2006

Related Questions

Does intramuscular ceftriaxone (Rocephin) provide coverage against gram-negative rods?
What class of antibiotics does ceftriaxone belong to?
When should ceftriaxone be administered by injection (intravenous infusion or deep intramuscular) and what are the appropriate indications?
What are the recommended administration routes, dosing, and dilution guidelines for ceftriaxone?
Can ceftriaxone (Trax‑S) injection be administered intravenously in a 20 mL normal‑saline dilution?
In a hypertensive patient whose blood pressure is well controlled with amlodipine and atenolol, can deflazacort be prescribed for inflammation due to another condition?
In a patient with a history of nephrolithiasis who is taking atorvastatin, should the calcium present as an inert filler in the tablet be a concern?
What is the recommended fenofibrate dosing for a patient with chronic kidney disease stage IV (eGFR ≈ 15‑29 mL/min)?
What laser parameters and treatment protocol are recommended for hair and tattoo removal in patients with Fitzpatrick skin types IV‑VI (darker skin)?
What are the recommended dosing regimens, administration instructions, and safety considerations for bilastine in adults and children?
What is the likely diagnosis and appropriate management for a patient with serum iron 30 µg/dL, ferritin 118 ng/mL, transferrin saturation (TSAT) 18 %, total iron‑binding capacity (TIBC) 169 µg/dL, and unsaturated iron‑binding capacity (UIBC) 139 µg/dL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.